Heterologous Prime-Boost Vaccination with MF59-Adjuvanted H5 Vaccines Promotes Antibody Affinity Maturation towards the Hemagglutinin HA1 Domain and Broad H5N1 Cross-Clade Neutralization

Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo

(2014) David J DiLillo et al.   NATURE MEDICINE

DNA Priming Prior to Inactivated Influenza A(H5N1) Vaccination Expands the Antibody Epitope Repertoire and Increases Affinity Maturation in a Boost-Interval–Dependent Manner in Adults

(2013) Surender Khurana et al.   JOURNAL OF INFECTIOUS DISEASES

Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses

(2013) F. Spensieri et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diversity Among Memory B Cells: Origin, Consequences, and Utility

(2013) D. Tarlinton et al.   SCIENCE

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

(2012) Nathalie Garçon et al.   Expert Review of Vaccines

Oligomeric Recombinant H5 HA1 Vaccine Produced in Bacteria Protects Ferrets from Homologous and Heterologous Wild-Type H5N1 Influenza Challenge and Controls Viral Loads Better than Subunit H5N1 Vaccine by Eliciting High-Affinity Antibodies

(2012) S. Verma et al.   JOURNAL OF VIROLOGY

AID Activity in B Cells Strongly Correlates with Polyclonal Antibody Affinity Maturation in-vivo Following Pandemic 2009-H1N1 Vaccination in Humans

(2012) Surender Khurana et al.   PLoS Pathogens

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

(2011) Jens Wrammert et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants

(2011) Whitney E. Purtha et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Immune Response Following H1N1pdm09 Vaccination: Differences in Antibody Repertoire and Avidity in Young Adults and Elderly Populations Stratified by Age and Gender

(2011) Surender Khurana et al.   JOURNAL OF INFECTIOUS DISEASES

MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines

(2011) S. Khurana et al.   Science Translational Medicine

Influenza vaccine immunology

(2010) Philip R. Dormitzer et al.   IMMUNOLOGICAL REVIEWS

H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses

(2010) Philippe Moris et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus

(2010) S. Khurana et al.   Science Translational Medicine

MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults

(2009) Angelika Banzhoff et al.   PLoS One

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody Recognition of a Highly Conserved Influenza Virus Epitope

(2009) D. C. Ekiert et al.   SCIENCE

Antigenic Fingerprinting of H5N1 Avian Influenza Using Convalescent Sera and Monoclonal Antibodies Reveals Potential Vaccine and Diagnostic Targets

(2009) Surender Khurana et al.   PLOS MEDICINE

Antigenically Distinct MF59-Adjuvanted Vaccine to Boost Immunity to H5N1

(2008) Iain Stephenson et al.   NEW ENGLAND JOURNAL OF MEDICINE